Back to News
Market Impact: 0.25
Inventiva Reports Final Patient Visit In Phase 3 NATiV3 Study For Lanifibranor; Topline Data In Q4
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Inventiva (IVA) announced the last patient visit in its Phase 3 NATiV3 trial of lanifibranor for MASH with moderate to advanced fibrosis. While no efficacy or timing for topline results was provided, completing enrollment/progressing to late-stage readouts is a constructive clinical milestone. Overall, the update modestly improves sentiment toward the program’s potential.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
IVEVF0.45
More News
- Nvidia CEO Jensen Huang emerges as Trump's top ally in AI safety debate
- GE Aerospace Goes Vertical (Integration)
- Williams-Sonoma's stock has soared in a sluggish housing market. Here's how it won over Wall Street
- DPM Metals Expands Brevene Porphyry South Discovery with New High-Grade Intercepts
- Budget airline king Bill Franke warms to first-class seats and premium upgrades
- U.S.-China gastrodiplomacy: Despite political tension, fast food chains from both countries gain popularity in each other’s territory
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Unstructured Data Search, Ask AI, and Advanced Futures Data
- Best AI Stock Research Tools for Professional Investors